Clinical trials: T-lymphocytes
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Gastric and Gastroesophageal Junction Adenocarcinoma
Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
To evaluate the safety and tolerability of AMG 910 in adult subjects, and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
- Trial name
- NCT04260191
- Testing
- AMG 910
- Where
- 20 sites in United States, Austria and 7 more
- Volunteers
- 15 people
- Sponsor
- Amgen
Lymphoma
CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy
The purpose of this study is to determine the efficacy and safety of CD22/CD19-targeted CAR-T cell immunotherapy as consolidation therapy after second-line treatment in patients with high-risk aggressive B-cell lymphoma.
- Trial name
- NCT07779018
- Testing
- CD22/CD19 CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Liping Dou
Acute Lymphoblastic Leukemia in Remission
CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors combined with CD19 positive feeder T cells treatment for CD19+…
- Trial name
- NCT05381662
- Testing
- CD19 CAR-T cells and CD19 positive feeder T cells
- Where
- 3 sites in China
- Volunteers
- 10 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
HIV/AIDS
Effect of Chidamide Combined With CAT-T or TCR-T Cell Therapy on HIV-1 Latent Reservoir
To study the safety and effectiveness of the combination of Chidamide with Chimeric Antigen Receptor(CAR)-T or T cell receptor(TCR)-T cell therapy on HIV patients based on cART.
- Trial name
- NCT03980691
- Testing
- Chidamide with CAR-T or TCR-T cell therapy
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Guangzhou 8th People's Hospital
Graft Versus Host Disease
Detection of Graft Versus Host Disease With [18F]F-AraG
This is a single-center imaging study to determine utility of in vivo imaging with [18F]F-AraG to identify sites of Graft Versus Host Disease (GVHD) in patients highly suspected of having acute GVHD who require systemic therapy…
- Trial name
- NCT03367962
- Testing
- [18F]F-Ara-G
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- CellSight Technologies, Inc.
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Infection, Precancerous/Nonmalignant Condition
Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection
RATIONALE: Collecting the T cells from a donor and transplanting them into a patient may be effective treatment for immunodeficiency syndrome and CMV infection.
- Trial name
- NCT00547235
- Testing
- therapeutic allogeneic lymphocytes, allogeneic bone marrow transplantation, total-body irradiation
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
PTCL, TRBC1 ADC
A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma
FG-M131 for injection is an antibody-drug conjugate (ADC) targeting the T-cell receptor beta chain constant region 1 (TRBC1). TRBC1 is a subunit of the αβ T-cell receptor (TCR) complex.
- Conditions
- PTCL, TRBC1 ADC, CTCL
- Trial name
- NCT07758491
- Testing
- FG-M131
- Where
- China
- Volunteers
- 110 people
- Sponsor
- FutureGen Biopharmaceutical (Beijing) Co., Ltd
Rheumatoid Arthritis
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care…
- Trial name
- NCT05782335
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma
To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.
- Trial name
- NCT05380635
- Testing
- Hypericin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Soligenix
Relapsed/Refractory Aggressive B-Cell Malignancies
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.
- Trial name
- NCT05588440
- Testing
- ONCT-808, Bridging Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Oncternal Therapeutics, Inc
Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
TmPSMA-02 in mCRPC
This is a Phase I, open-label dose finding study to assess the safety, tolerability, manufacturing feasibility, and preliminary efficacy of TmPSMA-02 CAR T cells in patients with metastatic castrate-resistant prostate cancer…
- Trial name
- NCT06046040
- Testing
- TmPSMA-02 CAR T Cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Pennsylvania
Type 1 Diabetes Mellitus (T1DM), Type 1 Diabetes Mellitus
Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 Diabetes
This study tests a three-phase immune treatment for people recently diagnosed with Type 1 diabetes (within 6 months, with some insulin production remaining).
- Conditions
- Type 1 Diabetes Mellitus (T1DM), Type 1 Diabetes Mellitus, Autoimmune Diabetes
- Trial name
- MATIN-2 (NCT07610213)
- Testing
- Teplizumab, Intralymphatic Insulin Immunotherapy (ILIT)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Abdullah Kars
Lymphoma
CAR-T Cell Induced Cardiac Dysfunction: A Prospective Study
In this observational, prospective study, patients affected by B-cell Lymphoma and candidate to chimeric antigen receptor-T (CAR-T) cell infusion will be evaluated at three timepoints to establish the rate of cardiac dysfunction…
- Trial name
- CARdio-Tox (NCT06106776)
- Testing
- Chimeric Antigen Receptor
- Volunteers
- 48 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Schimke Immuno-osseous Dysplasia
Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the Treatment of SIOD
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allo-HSCT and Kidney Transplantation in the treatment of Schimke immuno-osseous dysplasia
- Trial name
- NCT06769191
- Testing
- CD7 CAR-T cells injection, Allo-HSCT, Kidney Transplantation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- NCT06909110
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jessie L. Alexander
Cancer Disease
GD2/CD70 Bi-specific CAR-T Cell Therapy
The purpose of this study is to assess the feasibility, safety and efficacy of GD2/CD70 bi-specific CAR-T cell therapy in patients with GD2 and/or CD70 positive tumor.
- Trial name
- NCT05438368
- Testing
- bi-4SCAR GD2/CD70 T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma
Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma
The goal of this clinical trial is to study how approaches for manufacturing chimeric antigen receptor (CAR)-modified T (CAR-T) cells affect their in vivo persistence and therapeutic efficacy against B lymphoma.
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- MeCAR (NCT02652910)
- Testing
- CD19.CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xinqiao Hospital of Chongqing
ANCA Associated Vasculitis, CMV Infection
CMV Modulation of the Immune System in ANCA-associated Vasculitis
The purpose of this study is to determine whether Cytomegalovirus (CMV) reactivation in ANCA-associated vasculitis (AAV) patients can be effectively and safely reduced using an antiviral agent (valaciclovir) and whether this in…
- Trial name
- CANVAS (NCT01633476)
- Testing
- Valaciclovir
- Where
- United Kingdom
- Volunteers
- 38 people
- Sponsor
- Professor Lorraine Harper